SyntekaBio Inc - Asset Resilience Ratio
SyntekaBio Inc (226330) has an Asset Resilience Ratio of 26.99% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 226330 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2022)
This chart shows how SyntekaBio Inc's Asset Resilience Ratio has changed over time. See net asset quality index of SyntekaBio Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down SyntekaBio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of SyntekaBio Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩11.57 Billion | 26.99% |
| Short-term Investments | ₩150.00 | 0.0% |
| Total Liquid Assets | ₩11.57 Billion | 26.99% |
Asset Resilience Insights
- Very High Liquidity: SyntekaBio Inc maintains exceptional liquid asset reserves at 26.99% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
SyntekaBio Inc Industry Peers by Asset Resilience Ratio
Compare SyntekaBio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Waystar Holding Corp. Common Stock
NASDAQ:WAY |
Health Information Services | 2.13% |
|
Oneview Healthcare Plc
AU:ONE |
Health Information Services | 29.71% |
|
Forian Inc
NASDAQ:FORA |
Health Information Services | 42.25% |
|
Intrasense
PA:ALINS |
Health Information Services | 15.68% |
|
Pro Medicus Ltd
AU:PME |
Health Information Services | 54.64% |
|
Echoiq Ltd
AU:EIQ |
Health Information Services | 11.12% |
|
ARTRYA Ltd
AU:AYA |
Health Information Services | 32.70% |
|
Cogstate Ltd
AU:CGS |
Health Information Services | 54.90% |
Annual Asset Resilience Ratio for SyntekaBio Inc (2017–2022)
The table below shows the annual Asset Resilience Ratio data for SyntekaBio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 63.46% | ₩35.34 Billion ≈ $23.95 Million |
₩55.69 Billion ≈ $37.74 Million |
-14.19pp |
| 2021-12-31 | 77.65% | ₩52.71 Billion ≈ $35.72 Million |
₩67.88 Billion ≈ $46.00 Million |
-14.11pp |
| 2020-12-31 | 91.77% | ₩41.09 Billion ≈ $27.85 Million |
₩44.78 Billion ≈ $30.35 Million |
-2.54pp |
| 2019-12-31 | 94.31% | ₩45.22 Billion ≈ $30.64 Million |
₩47.95 Billion ≈ $32.49 Million |
+9.32pp |
| 2018-12-31 | 84.98% | ₩10.29 Billion ≈ $6.97 Million |
₩12.11 Billion ≈ $8.21 Million |
+37.45pp |
| 2017-12-31 | 47.53% | ₩1.19 Billion ≈ $806.36K |
₩2.50 Billion ≈ $1.70 Million |
-- |
About SyntekaBio Inc
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, di… Read more